TAK-875
- CAS No.
- 1000413-72-8
- Chemical Name:
- TAK-875
- Synonyms
- TAK875;Fasiglifam;CS-54;TAK-875,TAK875;TAK-875, >=98%;TAK875 USP/EP/BP;TAK-875(Fasiglifam);FASIGLIFAM (TAK-875);TAK-875; TAK875; TAK 875.;Fasiglifam, 10 mM in DMSO
- CBNumber:
- CB52534865
- Molecular Formula:
- C29H32O7S
- Molecular Weight:
- 524.63
- MDL Number:
- MFCD18251445
- MOL File:
- 1000413-72-8.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| Melting point | 123-127°C |
|---|---|
| Boiling point | 739.1±60.0 °C(Predicted) |
| Density | 1.252 |
| storage temp. | Refrigerator |
| solubility | Acetonitrile (Slightly), DMSO (Slightly), Methanol (Slightly) |
| pka | 4.36±0.10(Predicted) |
| form | Solid |
| color | White to Off-White |
| InChIKey | BZCALJIHZVNMGJ-HSZRJFAPSA-N |
| SMILES | O1C2=CC(OCC3C=CC=C(C4=C(C)C=C(OCCCS(C)(=O)=O)C=C4C)C=3)=CC=C2[C@H](CC(O)=O)C1 |
| FDA UNII | GLP1W4JXAH |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H315-H319-H335 | |||||||||
| Precautionary statements | P261-P305+P351+P338 | |||||||||
| NFPA 704 |
|
TAK-875 price More Price(66)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 17335 | TAK-875 ≥95% | 1000413-72-8 | 500μg | $49 | 2026-04-30 | Buy |
| Cayman Chemical | 17335 | TAK-875 ≥95% | 1000413-72-8 | 1mg | $86 | 2026-04-30 | Buy |
| Cayman Chemical | 17335 | TAK-875 ≥95% | 1000413-72-8 | 5mg | $329 | 2026-04-30 | Buy |
| Cayman Chemical | 17335 | TAK-875 ≥95% | 1000413-72-8 | 10mg | $469 | 2026-04-30 | Buy |
| TRC | TRC-T004915-5MG | TAK-875 | 1000413-72-8 | 5mg | $100 | 2026-06-03 | Buy |
TAK-875 Chemical Properties, Uses, Production
Description
The free fatty acid receptor 1 (FFAR1; GPR40) is highly expressed in pancreatic β-cells and activated by medium and long-chain fatty acids. There is evidence of a link between FFAR1 (GPR40) and the ability of fatty acids to amplify glucose-stimulated insulin secretion, making this signaling pathway a potential target for regulating diabetes, obesity, and other metabolic disorders. TAK-875 is a selective FFAR1 (GPR40) agonist (EC50 = 26 nM) that does not exhibit activity on the related FFARs FFAR2 (GPR43) or FFAR3 (GPR41).
Uses
TAK-876 is a selective G protein-coupled receptor 40 (GPR40) agonist. TAK-876 is a novel oral medication that has been developed to improve the secretion of insulin in a glucose-dependent manner, whic h has the potential to improve the control of blood sugar levels without the risk of hypoglycemia.
Uses
TAK-876 is a selective G protein-coupled receptor 40 (GPR40) agonist (1,2). TAK-876 is a novel oral medication that has been developed to improve the secretion of insulin in a glucose-dependent manner, which has the potential to improve the control of blood sugar levels with a low risk of hypoglycemia.
Definition
ChEBI: Fasiglifam is a member of biphenyls.
in vitro
tak-875 exhibited potent agonist activity and high binding affinity to the human receptor. in addition, tak-875 showed excellent agonist potency selectivity for gpr40 receptor over other members of the ffa receptor family (for which ec50>10 μm) [1].
in vivo
tak-875 showed potent plasma glucose-lowering action and insulinotropic action during an oral glucose tolerance test in female wistar fatty rats with impaired glucose tolerance [2].
target
GPR40
References
[1] negoro n, sasaki s, mikami s, ito m, suzuki m, tsujihata y, ito r, harada a, takeuchi k, suzuki n, miyazaki j, santou t, odani t, kanzaki n, funami m, tanaka t1, kogame a, matsunaga s, yasuma t, momose y. discovery of tak-875: a potent, selective, and orally bioavailable gpr40 agonist. acs med chem lett. 2010 jun 18;1(6):290-4.
[2] leifke e, naik h, wu j, viswanathan p, demanno d, kipnes m, vakilynejad m. a multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel gpr40 agonist, tak-875, in subjects with type 2 diabetes. clin pharmacol ther. 2012 jul;92(1):29-39.
TAK-875 Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Wuhan Acumen Bio-Technology Co.,ltd | 027-027-16602739303 16602739303 | 673003916@qq.com | China | 4593 | 58 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| Shanghai jerryxing Biomedical Technology Co., Ltd | 17521512546 17721492509 | 460170712@qq.com | China | 4996 | 58 |
| Shanghai Boyle Chemical Co., Ltd. | sales@boylechem.com | China | 2915 | 55 | |
| J & K SCIENTIFIC LTD. | 18210857532 18210857532 | jkinfo@jkchemical.com | China | 96815 | 76 |
| Chembest Research Laboratories Limited | 021-20908456 | sales@BioChemBest.com | China | 5996 | 61 |
| Shanghai Longsheng chemical Co.,Ltd. | 58099637 13585536065 | sales@shlschem.com | China | 9880 | 59 |
| Chemsky（shanghai）International Co.,Ltd. | 021-50135380 | shchemsky@sina.com | China | 32273 | 50 |
| Tongchuang Pharma(Suzhou). Co., Ltd. | 0512-63263366 18912765016 | tongtf110@sina.com | China | 984 | 62 |
| Dalian Meilun Biotech Co., Ltd. | 0411-62910999 13889544652 | sales@meilune.com | China | 4765 | 58 |
View Latest Price from TAK-875 manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-08-20 | TAK875 USP/EP/BP
1000413-72-8
|
$1.10 | 1g | 99.9% | 100 Tons min | Dideu Industries Group Limited | |
 |
2026-06-02 | Fasiglifam
1000413-72-8
|
$44.00-152.00 | 99.90% | 10g | TargetMol Chemicals Inc. |
-
- TAK875 USP/EP/BP
1000413-72-8
- $1.10
- 99.9%
- Dideu Industries Group Limited
-
- Fasiglifam
1000413-72-8
- $44.00-152.00
- 99.90%
- TargetMol Chemicals Inc.
